In light of new data at ESMO, researchers debated whether HER2-targeted tyrosine kinase inhibitors or antibody-drug conjugates might be better as initial treatment.
In the histology-centric world of cancer medicine, further work is needed to increase genomic testing rates and educate ...
Patients with a very rare immune disorder who have gotten the gene therapy have experienced sustained long-term immune ...
Kite has paid $120 million upfront to Pregene to gain certain license rights and to collaborate on developing in vivo cell therapies with the Shenzhen, China-based firm. Pregene is entitled to receive ...
The agency launched the Commissioner's National Priority Voucher pilot program to quickly approve products that could address national interests.
Patients who had adjuvant Verzenio with endocrine therapy had a small but significant improvement in survival versus endocrine therapy alone.
The funding includes an initial tranche of $7.5 million in equity and technical support, and the biotech and foundation will form a joint steering committee.
Trial initiation triggered a $250 million payment to SystImmune from Bristol Myers Squibb, under a 2023 collaboration and license agreement.
NEW YORK – Akari Therapeutics on Wednesday said it hopes to raise $2.5 million by selling 3,125,000 American depositary shares (ADS) in a registered direct offering.
The firm continues to seek needed funds to launch a Phase I/II trial of ELP-02 for this extremely rare form of ...
Enhertu Benefit in HER2-Low Breast Cancer That's Also HR-Negative Supported by Longer Follow-Up Data
Like with HR-positive patients, researchers found that patients with HR-negative or ER-low tumors lived longer on Enhertu than chemo after nearly three years.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback